Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8
Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.
Share
Why It Matters
An expert investor watcher thinks Myriad Genetics is worth more money now. They believe the company is doing well and have more confidence in it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.